100 15–6 117 print - Karger Publishers

International Journal of Experimental and Clinical Pharmacology

Original Papers

209 Trigonelline Inhibits Inflammation and Protects β

Cells to Prevent Fetal Growth Restriction during

Pregnancy in a Mouse Model of Diabetes

Zhou, J.-Y.; Du, X.-H.; Zhang, Z.; Qian, G.-S. (Chongqing)

218 Oxamate Enhances the Anti-Inflammatory and

Insulin-Sensitizing Effects of Metformin in Diabetic

Mice

Wu, M.; Ye, W.; Zheng, Y.; Zhang, S. (Guangzhou)

229 A “Prozone-Like” Effect Influences the Efficacy of the

Monoclonal Antibody ABT-700 against the Hepatocyte

Growth Factor Receptor

Vaidya, K.S.; Oleksijew, A.; Tucker, L.A.; Pappano, W.N.; Anderson, M.G. (North Chicago, IL); Grinnell, C.M. (Worcester, MA); Zhang, Q. (North Chicago, IL); Heighton, S.J. (Worcester, MA); Mitten, M.J.; Mishra, S.; Palma, J.P.; Wang, J.; Reilly, E.B.; Boghaert, E.R. (North Chicago, IL)

246 Paclitaxel Promotes Cell Apoptosis in Uterine

Leiomyomas

Liu, H.; Wang, J.; Sheng, L.; Zhang, Y.; Tang, N.; Li, Y.; Hao, T. (Jinan)

253 Resveratrol Attenuates Adriamycin-Induced

Focal Segmental Glomerulosclerosis through C3aR/

C5aR-Sphingosine Kinase 1 Pathway

Liu, G.; Wang, Q.; Shi, Y. (Changde); Peng, X.; Liu, H.; Peng, Y.; He, L. (Changsha)

261 Amiloride Is Effective in the Management of

Abiraterone-Induced Mineralocorticoid Excess

Syndrome without Interfering with Its

Antineoplastic Activity

Bedussi, F.; Galli, D.; Fragni, M.; Valcamonico, F.; Rossini, E.; Dalla Volta, A.; Vezzoli, S.; Roca, E.; Ferrari, V.; Lazzari, B.; Memo, M.; Sigala, S.; Berruti, A. (Brescia)

269 MiR-490-5p Suppresses Cell Proliferation and Invasion

by Targeting BUB1 in Hepatocellular Carcinoma Cells

Xu, B.; Xu, T.; Liu, H.; Min, Q.; Wang, S.; Song, Q. (Wuhan)

283 Heat Shock Protein 27, a Novel Regulator of

Transforming Growth Factor β Induced Resistance to

Cisplatin in A549 Cell

Huang, Z.; Yang, C.; Sun, S.; Nan, Y.; Lang, Z.; Wang, X.; Zhao, J.; Liu, Y. (Changchun)

292 Mechanistic Evaluation of the Protective Effect of

Carnosine on Acute Lung Injury in Sepsis Rats

Sun, C. (Nantong); Wu, Q. (Suzhou); Zhang, X.; He, Q.; Zhao, H. (Nantong)

301 Inhibitory Effect of Citalopram on the

Pharmacokinetics of Carvedilol in Rats and in vitro

Models

Abrudan, M.B.; Muntean, D.M.; Popa, D.S.; Gheldiu, A.-M.; Neag, M.A.; Vlase, L. (Cluj-Napoca)

Short Communication

243 Cerebrospinal Fluid Levels of 14-3-3 Gamma:

What Does It Tell Us About Sporadic Creutzfeldt-Jakob

Disease?

Humpel, C.; Benke, T. (Innsbruck)

308 Acknowledgement to Referees for 2017

310 Contents Vol. 100, 2017after

S. Karger

Medical and Scientific Publishers

Basel . Freiburg . Paris .

London . New York . Chennai .

New Delhi . Bangkok . Beijing .

Shanghai . Tokyo . Kuala Lumpur .

Singapore . Sydney

Pharmacology

100(5–6) 209–310 (2017) 100 | 5–6 | 17print

ISSN 0031–7012

online

e-ISSN 1423–0313

www.karger.com/pha

This journal publishes original research articles and state-of-the-art re-

views on all aspects of antimicrobial and antitumor chemotherapy. The

results of experimental and clinical investigations into the microbio-

logical and pharmacologic properties of antibacterial, antiviral and

antitumor compounds are major topics of publication. Papers selected

for the journal offer data concerning the efficacy, toxicology, and inter-

actions of new drugs in single or combined applications. Studies de-

signed to determine the pharmacokinetic and pharmacodynamic

properties of similar preparations and comparing their efficacy are also

included. Special emphasis is given to the development of drug-resis-

tance, an increasing problem worldwide.

Chemotherapy

Founded: 1959

Category: Clinical and Basic Research

Fields of Interest: Infectious Diseases, Oncology

Listed in bibliographic services, including:

PubMed/MEDLINE, Web of Science, Google Scholar, Scopus, Embase

2018: Volume 63

6 issues per volume

Language: English

ISSN 0009–3157

e-ISSN 1421–9794

More information at w w w.karger.com/che

An international forum on all aspects of antimicrobial and antitumor chemotherapy

Impact Factor: 0.843

International Journal of Experimental and Clinical Chemotherapy

Editor-in-Chief

G. Minotti, Rome

Associate Editors

G. Delogu, RomeG. Graziani, Rome

Selected contributions

• Gemcitabine-Induced Subacute Cutaneous Lupus Erythematosus:

A Case Report: Ben Zvi M. (Tel Aviv) et al.

• New Perspectives in the Treatment of Advanced Gastric Cancer:

S-1 as a Novel Oral 5-FU-Therapy in Combination with Cisplatin: Heinemann V. (München) et al.

• Clinical Practice of Adjuvant Chemotherapy in Patients with Early-Stage

Epithelial Ovarian Cancer: Frielink L.M. (Maastricht/Eindhoven) et al.

• Potential of Casiopeínas® Copper Complexes and Antituberculosis Drug

Combination against Mycobacterium tuberculosis: Barbosa A.R. (São Paulo)

et al.

• Anti-CCR4 Monoclonal Antibody Mogamulizumab Followed by the

GDP (Gemcitabine, Dexamethasone and Cisplatin) Regimen in Primary

Refractory Angioimmunoblastic T-Cell Lymphoma: Kato H. (Nagoya) et al.

• Antimicrobial Susceptibility among European Gram-Negative and

Gram-Positive Isolates Collected as Part of the Tigecycline Evaluation

and Surveillance Trial (2004–2014): Rodloff A.C. (Leipzig); Dowzicky M.J.

(Collegeville, Pa.)

• Clarithromycin Dose-Dependently Stabilizes Rat Peritoneal Mast Cells: Kazama I. (Sendai) et al.

• Characterization of Integrons and Sulfonamide Resistance Genes

among Bacteria from Drinking Water Distribution Systems in

Southwestern Nigeria: Adesoji A.T.; Ogunjobi A.A. (Ibadan); Olatoye I.O.

(Ibadan/Pullman, Wash.)

• Do You Know Pixantrone?: Minotti, G.; Menna, P.; Salvatorelli, E. (Rome)

• Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief

Overview: Menna, P.; Salvatorelli, E. (Rome)

KF1

80

26

Printed in Germany on acid-free and non-aging paper (ISO 9706) by Stückle Druck, Ettenheim

International Journal of Experimental and Clinical Pharmacology

Founded 1959 as “Medicina Experimentalis”, continued 1965–1967 as“Medicina et Pharmacologia Experimentalis”Founder: R. Domenjoz (1959–1977)Successors: B.B. Brodie (1968–1977); K. Lederis (1973–1985); K.-F. Sewing (1978–1998); E.S. Vesell (1970–2000); R. Kato (1992–1995); T. Watanabe (1995–2001); T. Iijima (2002–2006); M.L. Billingsley (2001–2013)

Editors

J. Donnerer, GrazK. Takeuchi, KyotoK.E. Vrana, Hershey, PA

Editorial Board

C. Antoniou, AthensJ. Ahrens, HannoverL.Z. Benet, San Francisco, CAM.L. Billingsley, Hershey, PAA. Breckenridge, LondonK.K. Burkhart, Silver Spring, MDG. Coruzzi, ParmaS. Dhein, LeipzigT.L. Goodfriend, Madison, WIL.S. Harris, Richmond, VAM. Hirafuji, Ishikari-TobetsuM.D. Hollenberg, Calgary, ABM. Inui, YamaguchiK. Ishii, YamagataC. Joukhadar, Boston, MA

Y. Kamisaki, OsakaN. Kaplowitz, Los Angeles, CAA. Kawabata, OsakaA. Levitzki, JerusalemB.R. Lucchesi, Ann Arbor, MIW.E. Müller, Frankfurt am MainN.H. Neff, Columbus, OHJ.P. O’Callaghan, Morgantown, WVK. Pennypacker, Tampa, FLS. Saha, Kansas City, MTC. Scarpignato, NantesC.D. Smith, Charlestown, SCE. Taira, IwateC. Zeng, Chongqing City

Fax +41 61 306 12 34 E-Mail [email protected] www.karger.com

© 2017 S. Karger AG, Basel

The Guidelines for Authors are available at: www.karger.com/pha_Guidelines

Guidelines for Authors

SubmissionThe journal publishes articles dealing with all aspects of experimental and clinical pharmacology. Papers dealing with mechanistic aspects at a molecular lev-el are particularly encouraged. They can be full arti-cles as well as short communications of investigative findings. Reviews, comments and perspective notes on timely topics are specifically welcome. Reviews in which a specific field is reviewed through an ex-haustive literature survey. An Abstract is required and should be divided into Background, Summary and Key Messages. Review Articles should consist of a maximum of 4,000 words. We consider investi-gations dealing with biological extracts or with phy-topharmaceutical preparations as outside the scope of our journal. Only papers written in English are considered and should be submitted using the on-line submission website at:

www.karger.com/pha

or sent as e-mail attachment (the preferred word-processing package is MS-Word) to the Editorial Office:

[email protected]

Prof. J. DonnererS. Karger AGEditorial Office “Pharmacology”P.O. BoxCH–4009 Basel (Switzerland)Tel. +41 61 306 1356Fax +41 61 306 1434

Names, postal and e-mail adresses of 4 experts in the appropriate area of research should accompany each manuscript. Referees suggested should not be from the same institution or be research collabora-tors of the author(s).

ConditionsAll manuscripts are subject to editorial review. Manu scripts which do not properly consider eth-ical issues for humans or animals will not be ac-cepted for publication. In the “Methods” section, it is recommended to mention the approval given by the responsible authorities. Manu scripts are re-ceived with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Pharmacology and may not be reproduced by any means, in whole or in part, without the written consent of the pub-lisher. It is the author’s responsibility to obtain per-mission to reproduce illustrations, tables, etc. from other publications.

Conflicts of InterestAuthors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be pub-lished at the end of the article.

Plagiarism PolicyWhether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of pla-giarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

EthicsPublished research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute’s committee on hu-man research. Further, they should also state that animal experiments conform to institutional stan-dards.

ArrangementTitle page: The first page of each paper should indi-cate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the cor-responding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract of Reviews: Should be divided into the fol-lowing subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise de-scription of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review.

Abstract of Original Papers or Short Communica-tions: Each paper needs an abstract of up to 10 lines.

Drug names: Authors are requested to use Inter-national non-proprietary names definitely recom-mended or, if no final recommendation has been made, proposed by the World Health Organisation (WHO). The use of laboratory code numbers ne-cessitates prior explanation by chemical name or structural formula.

Footnotes: Avoid footnotes.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a head-ing and figures a legend, also prepared on a sepa-rate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for

reproduction (max. size 180 223 mm) or provide crop marks. Each illustration must be labeled with its number and the first author’s name. The final resolution for b/w half-tone and color illustrations must be 300 dpi after scaling. Line drawings require 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (for detailed instructions, see http://www.karger.com/pha).

Color illustrationsOnline edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid re-ferring to the colors in the text and figure legends. Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data]and not be included in the ref-erence list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The sur-names of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform re-quirements for manuscripts submitted to biomedi-cal journals (www.icmje.org).

Examples (a) Papers published in periodicals: Sun J, Koto H, Chung KF: Interaction of ozone and allergen chal-lenges on bronchial responsiveness and inflamma-tion in sensitised guinea pigs. Int Arch Allergy Im-munol 1997;112:191–195.(b) Papers published only with DOI numbers:Theoharides TC, Boucher W, Spear K: Serum inter-leukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.(c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics, ed 3, revised. Basel, Karger, 1996.(d) Edited books: Parren PWHI, Burton DR: Anti-bodies against HIV-1 from phage display libraries: Mapping of an immune response and progress to-wards antiviral immunotherapy; in Capra JD (ed): Antibody Engineering. Chem Immunol. Basel, Kar-ger, 1997, vol 65, pp 18–56.

Reference Management Software: Use of EndNote is recommended for easy management and format-ting of citations and reference lists.

Digital Object Identifier (DOI)S. Karger Publishers supports DOIs as unique iden-tifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles pub-lished online without volume or issue information. More information can be found at www.doi.org.

Fax +41 61 306 12 34 E-Mail [email protected] www.karger.com

© 2017 S. Karger AG, Basel

The Journal Home Page is available at: www.karger.com/pha

Supplementary MaterialMultimedia files and other supplementary files, di-rectly relevant but not essential to the conclusions of a paper, enhance the online version of a publica-tion and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supple-mentary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modifica-tion or editing. Files should not exceed 10 Mb in size. Figures and tables need to have titles and leg-ends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figshare.com under a CC BY license. Authors will be charged a process-ing fee of CHF 250.00 for supplementary material.

Self-Archiving/Green Open AccessKarger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before produc-tion) on their personal or their institution’s internal website. In addition, authors may post their accept-ed manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Men-deley) no earlier than 12 months following publica-tion of the final version of their article. For all self-archiving, the posted manuscripts must: • Be used for noncommercial purposes only• Be linked to the final version on www.karger.com• Include the following statement:

“This is the peer-reviewed but unedited man-uscript version of the following article: [in-sert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].”

It is the author’s responsibility to fulfill these re-quirements.For papers published online first with a DOI num-ber only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Kar- ger on the author’s behalf [see Funding Organiza-tions (NIH etc.)].For self-archiving Author’s ChoiceTM (Gold Open Access) articles, see Author’s ChoiceTM.

Author’s ChoiceTM

Karger’s Author’s ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a per-missible cost in grant allocation. More information can be found at www.karger.com/authors_choice.The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must: • Follow the terms of the relevant Creative Com-

mons license• Be linked to the final version on www.karger.com• Include the following statement:

“The final, published version of this article is avail-able at http://www.karger.com/?doi=[insert DOI number].”

It is the author’s responsibility to fulfill these re-quirements. For papers published online first with a DOI num-ber only, full citation details must be added as soon as the paper is published in its final version. This is

important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)The U.S. National Institutes of Health (NIH) Pub-lic Access Policy mandates that accepted, peer-re-viewed manuscripts are archived in its digital data-base, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on be-half of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC af-ter a 12-month embargo. For authors making their paper Open Access through Author’s ChoiceTM, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Well-come Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Page ChargesThere are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is equal to approx. 14 man-uscript pages (including tables, illustrations and references).

ProofsUnless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the au-thor.

ReprintsOrder form and price list is sent with the pdf proofs. Orders submitted after the issue is printed are sub-ject to considerably higher prices.

Fax +41 61 306 12 34 E-Mail [email protected] www.karger.com

© 2017 S. Karger AG, Basel

The Journal Home Page is available at: www.karger.com/pha

General Information

ISSN Print Edition: 0031–7012ISSN Online Edition: 1423–0313

Journal Homepage: www.karger.com/pha

Publication Data: Pharmacology is published 12 times a year. Volumes 99–100, each with 6 issues, appear in 2017.

Copyright: © 2017 S. Karger AG, Basel (Switzerland). All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, with-out permission in writing from the publisher.

Disclaimer: The statements, opinions and data con-tained in this publication are solely those of the indi-vidual authors and contributors and not of the publish-er and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or ap-proval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to per-sons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Subscription Rates: Subscriptions run for a full calendar year. Prices are given per year.Personal subscription:

Print or Online Print+Online combinedCHF 1803.00 CHF 1903.00EUR 1625.00 EUR 1705.00USD 1960.00 USD 2068.00postage and handling (added to print and print+online)CHF 96.00 Europe, CHF 139.20 OverseasEUR 86.40USD 134.40

Institutional subscription:Print or Online Print+Online combinedCHF 3606.00 CHF 4147.00 EUR 3249.00 EUR 3736.00USD 3920.00 USD 4508.00postage and handling (added to print and print+online)CHF 120.00 Europe, CHF 174.00 OverseasEUR 108.00USD 168.00

Back Volumes and Single Issues: Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Cus-tomer Service at [email protected].

Bibliographic Indices: This journal is regularly listed in bibliographic services, including Current Contents® and PubMed/MEDLINE.

Subscription Orders: Orders can be placed at any bookstore, subscription agency, directly with Karger Publishers, or with one of our representatives:

S. Karger AGMedical and Scientific Publishers P.O. Box4009 BaselSwitzerlandt: +41 61 306 11 11f: +41 61 306 12 34e: [email protected]: www.karger.com

(for courier services only:Allschwilerstrasse 104055 Basel/Switzerland)

Change of Address: Both old and new address should be sent to the subscription source.

GermanyS. Karger GmbHPostfach79095 FreiburgDeutschland(Hausadresse: Wilhelmstrasse 20A,79098 Freiburg)t: +49 761 45 20 70f: +49 761 45 20 714e: [email protected]: www.karger.de

JapanKarger Japan, Inc.Shiba Daimon Asahi Bldg. 2F1-2-23 Shiba DaimonMinato-kuTokyo 105-0012 Japant: +81 3 6435 6242f: +81 3 6435 6244e: [email protected]: www.karger.jp

USAS. Karger Publishers, Inc.26 West Avon RoadP.O. Box 529Unionville, CT 06085USAToll free: +1 800 828 5479t: +1 860 675 7834 f: +1 860 675 7302e: [email protected]

FranceEnter & ReadAlbertine Luginbuhl23, rue du Départ, boîte 3775014 ParisFrancet: +33 6 81 04 76 85e: [email protected]

South East Asia, China and TaiwanKarger Regional Office (Malaysia)Level 28-03-03A, PJ ExchangeNo. 16A, Persiaran Barat46050 Petaling JayaSelangor Darul EhsanMalaysiat: +60 3 7962 0158f: +60 3 7962 0001e: [email protected]; [email protected]

Karger China51F Raffles City Centre268 Xi Zang Middle RoadHuang Pu DistrictShanghai 200001P.R. Chinat: +86 21 2312 7673f: +86 21 2312 7777e: [email protected] [email protected]: www.karger.cn

India, Bangladesh, Sri LankaKarger IndiaG202 Jaipuria Sunrise GreenIndirapuramGhaziabad 201014Uttar PradeshIndiat: +91 98 10958 282e: [email protected]

Basel • Freiburg • Paris • London • New York • New Delhi • Bangkok • Beijing • Tokyo • Kuala Lumpur • Singapore • Sydney

Contents

See the journal website for contents

14Clinical

March 1-3, 2018 | Tel-Aviv, Israel

Current & Future Ocular Drug Therapy | DevicesTreatment algorithms Endpoints in clinical studies Phase 3 data - in your clinic

www.ISOPTclinical.com

F173

16

We are entering a new and exciting era of microbiological study and application. Recent advances in the now established disciplines of ge-nomics, proteomics and bioinformatics, together with extensive coop-eration between academic and industrial concerns have brought about an integration of basic and applied microbiology as never before. The Journal of Molecular Microbiology and Biotechnology (JMMB) aims to re-flect this development by publishing original research papers from all areas of microbiology and biotechnology. It also features written sym-posia on selected topics, timely reviews and minireviews. Theoretical approaches and descriptions of novel, microbiologically relevant soft-ware is also considered. Contributions and ideas from large segments of the scientific community are welcome to make JMMB a viable, much-needed and up-and-coming forum for current basic and applied mi-crobiological research.

Journal of Molecular Microbiology and BiotechnologyFounded: 1999Category: Basic ResearchFields of Interest: Biotechnology, Bioinformatics

Listed in bibliographic services, including: PubMed/MEDLINE, Web of Science,Google Scholar, Scopus, Embase

2018: Volume 286 issues per volumeLanguage: EnglishISSN 1464–1801e-ISSN 1660–2412

More information at w w w.karger.com/mmb

Reflecting the integration of basic and applied microbiology

Impact Factor: 1.25

Editor-in-ChiefM.H. Saier, Jr.,

La Jolla, CA

Senior EditorsM.H. Brown,

Adelaide, SAJ. Deutscher,

Thiverval-GrignonG. Gosset,

CuernavacaP. Graumann,

Marburg

M. Müller, Freiburg

D.H. Nies, Halle/Saale

R. Rabus, Oldenburg

Y. Zhao, La Jolla, CA

Selected contributions• Anaerobic Microbial Degradation of Hydrocarbons: From Enzymatic Reactions to the Environment: Rabus, R. (Oldenburg); Boll, M. (Freiburg); Heider, J. (Marburg); Meckenstock, R.U. (Neuherberg/Essen); Buckel, W. (Marburg); Einsle, O. (Freiburg); Ermler, U. (Frankfurt); Golding, B.T. (Newcastle upon Tyne); Gunsalus, R.P. (Los Angeles, Calif.); Kroneck, P.M.H. (Konstanz); Krüger, M. (Hannover); Lueders, T. (Neuherberg); Martins, B.M. (Berlin); Musat, F.; Richnow, H.H. (Leipzig); Schink, B. (Konstanz); Seifert, J. (Stuttgart); Szaleniec, M. (Kraków); Treude, T. (Kiel/Los Angeles, Calif.); Ullmann, G.M. (Bayreuth); Vogt, C. (Leipzig); von Bergen, M. (Leipzig/Aalborg); Wilkes, H. (Oldenburg/Potsdam)

• Escherichia coli mazEF Toxin-Antitoxin System as a to Target Cell Ablation in Plants: Baldacci-Cresp, F.; Houbaert, A.; Metuor Dabire, A.; Mol, A.; Monteyne, D.; El Jaziri, M.; Van Melderen, L.; Baucher, M. (Gosselies)

• Transport and Catabolism of Carbohydrates by Neisseria meningitides: Derkaoui, M. (Jouy-en-Josas/Paris); Antunes, A. (Paris); Nait Abdallah, J. (Jouy-en-Josas/Paris); Poncet, S.; Mazé, A.; Ma Pham, Q.M. (Jouy-en-Josas); Mokhtari, A. (Jouy-en-Josas/Guelma); Deghmane, A.-E. (Paris); Joyet, P. (Jouy-en-Josas); Taha, M.-K. (Paris); Deutscher, J. (Jouy-en-Josas/Paris)

• Transport and Catabolism of Pentitols by Listeria monocytogenes: Kentache, T.; Milohanic, E.; Cao, T.N. (Jouy-en-Josas); Mokhtari, A. (Jouy-en-Josas/Guelma); Aké, F.M.; Ma Pham, Q.M.; Joyet, P. (Jouy-en-Josas); Deutscher, J. (Jouy-en-Josas/Paris)

• Requirements for Septal Localization and Chromosome Segregation Activity of the DNA Translocase SftA from Bacillus subtilis: El Najjar, N. (Marburg); Kaimer, C. (Bochum); Rösch, T.; Graumann, P.L. (Marburg)

• Complete Sequence and Organization of pFR260, the Bacillus thuringi-ensis INTA Fr7-4 Plasmid Harboring Insecticidal Genes: Navas, L.E. (Castelar/Buenos Aires); Amadio, A.F. (Rafaela/Buenos Aires); Ortiz, E.M.; Sauka, D.H. (Castelar/Buenos Aires); Benintende, G.B. (Castelar); Berretta, M.F.; Zandomeni, R.O. (Castelar/Buenos Aires)

• Mating of 2 Laboratory Saccharomyces cerevisiae Strains Resulted in Enhanced Production of 2-Phenylethanol by Biotransformation of L-Phenylalanine: Mierzejewska, J.; Tymoszewska, A.; Chreptowicz, K.; Krol, K. (Warsaw)

KF18

060

KI 1

7173

Three BMA awards for Karger PublishersWe are delighted to announce that three Karger titles received ‘Highly Commended’ awards by the British Medical Association in their prestigious 2017 Medical Book Competition:

Interdisciplinary Topics inGerontology and Geriatrics

Editor: T. Fulop

Vol. 42

HIV and AgingEditors

M. Brennan-IngR.F. DeMarco

Current Problems in Dermatology

Editors: P. Itin, G.B.E. Jemec

Vol. 50

Itch – Management in Clinical Practice

Editors

J.C. Szepietowski E. Weisshaar

HIV and AgingEditors: Brennan-Ing, M. (New York, NY);

DeMarco, R.F. (Boston, MA)

X + 244 p., 12 fig., 12 tab., hard cover, 2017

ISBN 978–3–318–05945–8

e-ISBN 978–3–318–05946–5

www.karger.com/itoge

Itch – Management in Clinical PracticeEditors: Szepietowski, J. (Wroclaw);

Weisshaar, E. (Heidelberg)

VIII + 210 p., 28 fig., 26 in color, 36 tab.,

hard cover, 2016

ISBN 978–3–318–05888–8

e-ISBN 978–3–318–05889–5

www.karger.com/cupde

In the category ‘Medicine’ In the category ‘Internal Medicine’ In the category ‘Paediatrics’

SickKids Handbook of Pediatric Thrombosis and Hemostasis2nd, revised and extended edition

Editors: Blanchette, V.S.; Brandão, L.R. (Toronto, ON);

Breakey, V.R. (Hamilton, ON); Revel-Vilk, S. (Jerusalem)

XX + 338 p., 31 fig., 13 in color, 80 tab., hard cover, 2017

ISBN 978–3–318–03026–6

e-ISBN 978–3–318–03027–3

www.karger.com/sickkids

Karger titles which received awards in previous BMA Medical Book Competitions

www.karger.com

Olszewski and Baxter’s

Cytoarchitecture of theHuman BrainstemEditors

J.A. Büttner-EnneverA.K.E. Horn

3rd, revised and extended edition

Current Problems in Dermatology

Editors: P. Itin, G.B.E. Jemec

Vol. 48

Tattooed Skin and HealthEditors

J. SerupN. KlugerW. Bäumler

Developments in Ophthalmology

Editor: F. Bandello

Vol. 55

Retinal PharmacotherapeuticsEditors

Quan Dong NguyenEduardo B. Rodrigues Michel Eid Farah William F. MielerDiana V. Do

Immuno-Oncology Editors

O. MichielinG. Coukos

Progress in Tumor Research(formerly Progress in Experimental Tumor Research)

Editors: R.A. Stahel, S. Peters

Vol. 42

The extended and updated edition of this essential handbook

The easiest way to order : w w w.karger.com/sickkids

This handbook takes the reader through the entire field of

pediatric thrombosis and hemostasis and is updated to in-

clude new information and elements missing from the first

edition.

An introductory section concisely explains the complex

pathophysiology of hemostasis and thrombosis. The chap-

ters that follow include practical, evidence-based informa-

tion on the diagnosis and management of inherited and

acquired bleeding disorders and thrombotic events that

affect children. Special features include updated practical

clinical algorithms and appendices that cite normal labora-

tory reference ranges, bleeding and hypermobility scores, as

well as recommended dosages of blood products and major

hemostatic agents. An updated chapter on antithrombotic

therapy in children includes information on new anticoagu-

lants. A new chapter provides current information about

genetic testing and counseling in inherited bleeding and

clotting disorders.

Written and reviewed by international experts in the field,

this updated handbook is intended for health care profes-

sionals involved in the assessment and care of children with

inherited and acquired bleeding and clotting disorders. This

includes general and specialist pediatricians (in particular

intensivists, neonatologists, cardiologists/cardiac surgeons,

rheumatologists and nephrologists), hematologists/oncolo-

gists (pediatric and adult), as well as medical trainees, nurses,

nurse practitioners and pharmacists.

Contents

Contributors

Preface

Perspective: V.R. Breakey, L.R. Brandão, S. Revel-Vilk,

V.S. Blanchette

Coagulation, and Fibrinolysis: Understanding the Basics: S. Revel-Vilk, M.L. Rand, S.J. Israels

S. Revel-Vilk, M.L. Rand,

S.J. Israels

L. Avila, V.S. Blanchette

V. van Eimeren, S.J. Israels,

V.S. Blanchette, W.H.A. Kahr

E. Zapotocka, J.A. Curtin, V.S. Blanchette

V.R. Breakey, M. Carcao

F. Xavier,

S. Revel-Vilk, V.S. Blanchette

R. Kumar,

M. Steele

M. Rizzi, C. Barnes

V.E. Price, L.R. Brandão, S. Williams

S. Revel-Vilk, M. Albisetti,

M.P. Massicotte

V. Labarque, A.K.C. Chan, S. Williams

A. Andrade, N. Dlamini, S. Williams,

G. deVeber, R. Ichord

L.R. Brandão, Y. Diab, B.W. McCrindle

T. Biss, P. Monagle

R. Babul-Hirji, J. Di Paola,

D. Lillicrap

Appendices

M.L. Rand, V.S. Blanchette,

S.J. Israels, P.D. James

Clotting: P. Monagle, S. Revel-Vilk, M.L. Rand, V.R. Breakey,

W. Brien

M.F. Liebman,

E. Simpson, W. Lau, H.A. Hume

Utility of the Beighton Score: L. Banov, M. Carcao, R. Mendoza-Londono

R. Babul-Hirji, J. Di Paola,

D. Lillicrap

Abbreviations

SickKids Handbook of Pediatric Thrombosis and Hemostasis 2nd, revised and extended edition

Editors

Victor S. Blanchette, Leonardo R. Brandão, Vicky R. Breakey, Shoshana Revel-Vilk

BMA Medical Book Awards 2017 ‘highly commended’ in Paediatrics

Karger – Medical and Scientific Publishers

www.karger.com

would like to recommend it for our library.

Signature:

subscription agency, directly with the publisher

or through a Karger representative.

SickKids Handbook of Pediatric

Thrombosis and Hemostasis

2nd, revised and extended edition

personal customers